title: Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
authors.affiliation: *Thoracic Oncology Service, Department of Medicine; †Computational Biology Center; ‡Thoracic Service, Department of Surgery; §Department of Pathology, Memorial Sloan-Kettering Cancer Center; and ‖Weill Cornell Medical College, New York, NY.
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Hellmann
authors.forename: Boris
authors.initials: B
authors.lastname: Reva
authors.forename: Helena
authors.initials: H
authors.lastname: Yu
authors.forename: Valerie W
authors.initials: VW
authors.lastname: Rusch
authors.forename: Naiyer A
authors.initials: NA
authors.lastname: Rizvi
authors.forename: Mark G
authors.initials: MG
authors.lastname: Kris
authors.forename: Maria E
authors.initials: ME
authors.lastname: Arcila
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D000077192:Adenocarcinoma of Lung; D003198:Computer Simulation; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D008958:Models, Molecular; D017354:Point Mutation; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors